Short- and long-term cost-effectiveness of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis in China-Reference-Cited by-同舟云学术

Short- and long-term cost-effectiveness of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis in China

Published:2024-09-13 Issue: Volume: Page:1-15
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Shi Yin¹²,Zhou Yanwu²³,Li Shuishi²⁴,Guan Haijing⁵⁶,Liu Shao¹²

Affiliation:

1. Department of Pharmacy, Xiangya Hospital Central South University, Changsha, Hunan, China

2. National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University, Changsha, Hunan, China

3. Department of Thoracic Surgery, Xiangya Hospital Central South University, Changsha, Hunan, China

4. Department of General Surgery, Xiangya Hospital Central South University, Changsha, Hunan, China

5. Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

6. China Center for Health Economic Research, Peking University, Beijing, China

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2024.2403940

Reference44 articles.

1. Langan SM Irvine AD Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360.

2. Yamamura K Nakahara T. The Dawn of a New Era in Atopic Dermatitis Treatment. J Clin Med. 2022;11(20).

3. Guo Y Li P Tang J et al. Prevalence of Atopic Dermatitis in Chinese Children aged 1-7 ys. Sci Rep. 2016;6:29751.

4. Heng G Liping Y Yongsheng L et al. Survey on the Prevalence of Childhood Atopic Dermatitis in Ten Cities of China. Chin J Dermatol. 2004;37(1):29-31.

5. Hao F Zhang JZ. [The status and prospects of studies about atopic dermatitis]. Zhonghua Yi Xue Za Zhi. 2023;103(32):2465-2469.